Report from the (TCT) Scientific Symposium, 27 October – 1 November, San Francisco. A clinical trial shows that rapidly cooling patients who have suffered ST-elevation myocardial infarction (STEMI,… read more.
Report from the Transcatheter Cardiovascular Therapeutics (TCT) Scientific Symposium, 27 October – 1 November, San Francisco. Results of the EUROMAX trial presented at TCT 2013; findings simultaneously published… read more.
by Bruce Sylvester – Combined use of three DMARDs (disease-modifying antirheumatic drugs) for recent-onset rheumatoid arthritis (RA) is more effective than methotrexate monotherapy, researchers reported at the American… read more.
Children with juvenile idiopathic arthritis (JIA) undergoing early and aggressive combination drug therapy achieve clinical inactive disease more quickly than with less aggressive therapy, researchers reported at the… read more.
Treatment of psoriatic arthritis with early, aggressive pharmacologic intervention with disease-modifying antirheumatic drugs (DMARDs) while utilizing a a treat-to-target approach achieves better outcomes than standard care, researchers reported … read more.
by Bruce Sylvester – Anti-TNF treatment reduces risk of acute coronary syndrome, like heart attacks and angina, in rheumatoid arthritis patients, researchers reported at the American College of… read more.
by Bruce Sylvester – taken from the BMJ – British Medical Journal – Patients prescribed the smoking cessation drugs varenicline and buproprian are not at an increased risk… read more.
by Bruce Sylvester – taken from The Lancet – An investigative, single-pill combination drug shows efficacy for treating patients with the most difficult-to-treat types of hepatitis C, researchers… read more.
by Bruce Sylvester – taken from JAMA – Journal of the American Medical Association – A retrospective analysis of data on Danish women exposed to the nausea medication… read more.
by Bruce Sylvester – taken from the NEJM (New England Journal of Medicine) – Addition of nab-paclitaxel to gemcitabine for treatment of advanced pancreatic cancer has resulted in… read more.
by Esther Drain reporting on the presentation by Dr Timothy Price – A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated… read more.
Report by Esther Drain – Cetuximab resulted in a significant improvement in survival in TP53 WT, high-risk Rectal Cancer.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
